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Drug Delivery
TIRF Microscopy-Based Monitoring of Drug Permeation Across
a Lipid Membrane Supported on Mesoporous Silica
Paul Joyce,* Silver Jemetsa, Simon Isaksson, Shakhawath Hossain, Per Larsson,
Christel Bergstrçm, and Fredrik Hççk*
Abstract: There is an urgent demand for analytic approaches
that enable precise and representative quantification of the
transport of biologically active compounds across cellular
membranes. In this study, we established a new means to
monitor membrane permeation kinetics, using total internal
reflection fluorescence microscopy confined to a  500 nm
thick mesoporous silica substrate, positioned underneath
a planar supported cell membrane mimic. This way, we
demonstrate spatiotemporally resolved membrane permeation
kinetics of a small-molecule model drug, felodipine, while
simultaneously controlling the integrity of, and monitoring the
drug binding to, the cell membrane mimic. By contrasting the
permeation behaviour of pure felodipine with felodipine
coupled to the permeability enhancer caprylate (C8), we
provide evidence for C8-facilitated transport across lipid
membranes, thus validating the potential for this approach to
successfully quantify carrier system-induced changes to cellu-
lar membrane permeation.
The cellular exchange and transport of small molecule
bioactives are fundamental processes for biological activity
that are strictly regulated by the plasma membrane.[1] Under-
standing how small molecules traverse the cellular membrane
is therefore critical for the design and formulation develop-
ment of novel drug candidates, where promotion of efficient
cellular delivery is required to ensure desired therapeutic
activity and response.[2] However, simulating and predicting
the transport of small molecules across biological membranes
in vitro presents a significant challenge due to the lack of
facile, cost-effective and biologically relevant approaches that
deliver rapid and precise estimations of drug translocation.
In the context of oral drug delivery, small molecule
therapeutics must readily absorb across the intestinal epithe-
lium via transcellular and/or paracellular pathways to reach
the systemic circulation,[3] or be hosted within a carrier system
that promotes permeability, and thus bioavailability.[4] To
simulate this process and screen drug candidates/carrier
systems for permeability, static in vitro cellular models, such
as the Caco-2 cellular monolayer assay, have long been
regarded as the benchmark approach.[5] However, the cost-
and time-exhaustive nature of cellular assays, limited biolog-
ical relevancy,[6] and propensity for tight junction and/or cell
monolayer disruption, lead to complications in obtaining and
interpreting drug permeability kinetics with high accuracy.[7]
To overcome the hurdles associated with cellular assays,
recent focus has been attributed to developing representative
cell-membrane mimics as a simplified approach for in vitro
quantification of transcellular drug permeation.[8] In these
systems, phospholipid membranes are adsorbed onto a porous
polymeric support between a donor and acceptor cell,
allowing for the elucidation of time-dependent changes in
drug concentration within the acceptor cell.[9] While sup-
ported artificial membrane assays ignore paracellular trans-
port, several studies have demonstrated successful correla-
tions between in vitro and in vivo pharmacokinetics, thus
highlighting their ability to predict in vivo intestinal perme-
ability.[10] However, the formation and integrity of the lipid
membrane is neither monitored nor controlled using this
approach, which increases susceptibility for random drug flux
due to membrane disintegration.[11]
The aim of the present work was to overcome this
limitation by combining the supported membrane approach
with an analytical microscopy technique to validate bilayer
integrity throughout drug permeation studies, while simulta-
neously allowing for the detection and quantification of drug
permeation. This was accomplished using a  500 nm thick
mesoporous silica thin films (MSTF)[12] serving as substrate
for a supported lipid bilayer (SLB),[13] thereby enabling
concurrent fluorescence recovery after photobleaching
(FRAP) analysis of membrane integrity and total internal
reflection fluorescence (TIRF) spatiotemporal monitoring of
drug permeation into the MSTF.
Formation of the supported lipid bilayer (SLB) was
monitored with TIRF microscopy (Figure 1A), through the
inclusion of rhodamine-labelled tracer vesicles (Rh-
POPC),[14] on both non-porous (planar) and MSTF substrates
with a pore size of  7 nm.[12] The rate of POPC vesicle
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adsorption and rupture[15] was  2-fold greater on the planar
silica substrate, compared to the MSTF, which was attributed
to lower adhesion of vesicles to mesoporous silica; however,
despite subtle microscopic differences in the actual rupture
process, complete SLB formation over the entire surface was
observed on both substrates (Figure 1). The integrity of the
lipid membrane was verified using FRAP,[16] with substrate-
associated differences being observed for the diffusivity and
immobile fraction of labelled Rh-POPC lipids (Figure 1C).
The POPC bilayer adsorbed on MSTF exerted a  2-fold
greater diffusion constant (2.8 0.2 mm2 s1 vs. 1.4
0.2 mm2 s1) and 1.5-fold reduction in immobile fraction
(0.08 0.01 vs. 0.12 0.02), compared to the POPC bilayer
on the planar silica substrate. This agrees with previous
findings,[13] and accentuates that the influence of the substrate
on the lipid membrane is significantly lower for a porous
surface, when compared with a planar silica surface.
Before addressing drug permeation across SLBs formed
on mesoporous silica, the partitioning of the auto-fluorescent,
poorly water-soluble and orally administered drug, felodipine,
to SLBs formed on non-porous planar silica was investigated.
Felodipine was encapsulated and solubilized within colloidal
lipid vesicles (LVs; that is, mixed micelles and liposomes)[17]
composed of biologically relevant concentrations of phos-
pholipids and bile salts,[18] with and without the commonly
used transient permeation enhancer (PE), sodium caprylate
(C8). The inclusion of C8 (above its critical micelle concen-
tration) did not impact the extent of LVadsorption to the SLB
(Figure 2A and B), but triggered a greater degree of drug
spreading throughout the SLB, quantified by the time-
dependent increase in the diffuse diameter around the
adsorbed LVs (Figure 2C). These findings correlated closely
to changes in mean normalized fluorescence kinetics (Fig-
ure 2D), where LVs with and without C8 triggered a rapid
initial increase in fluorescence intensity (within 1 min) due to
vesicle adsorption onto the SLB, prior to a prolonged period
of gradually increasing fluorescence intensity, with a  2-fold
greater mean normalized fluorescence for felodipine, after
20 min, when hosted within LVs including C8, compared to
LVs alone. This is attributed to an increase in affinity of LVs to
SLB containing the C8 and felodipine, which is consistent
with the diffuse regions being visually brighter, suggesting
more pronounced LV binding, fusion to the SLB and even
aggregation, making them indistinguishable as individual
entities.
Previous studies have demonstrated that the primary
permeation enhancement mechanism of medium-chain fatty
acids, for example, C8, when dosed at high concentrations, is
to promote transcellular permeability by membrane pertur-
bation.[19] PE molecules have been reported to rapidly insert
and diffuse within lipid membranes,[20] which is in agreement
with the current findings, where C8 promoted greater
inclusion and diffusion of felodipine within the SLB. This
Figure 1. A) TIRF micrographs contrasting the rate and behavior of
SLB formation on a planar silica substrate versus MSTF (Scale
bars = 20 mm). B) Time-induced changes in the number of vesicles
adsorbed per 100  100 mm2 to a planar silica substrate (blue dots)
versus MSTF (red squares) during the formation of SLBs. C) Variations
in lipid membrane diffusion constant (green bars, left axis) and
relative immobile fractions (pink checkered bars, right axis) for SLBs
on planar and MSTF substrates. Data represents mean  S.D. (n = 3).
Figure 2. TIRF micrographs of SLBs formed on planar silica after
20 min incubation with auto-fluorescent felodipine hosted in A) LVs
and B) LVs with 100 mM C8. Scale bars = 20 mm. C) The number of
lipid vesicles adsorbed per 100  100 mm2 onto the SLB (green bars,
left axis) and the average degree of felodipine spreading within the
SLB (pink checkered bars, right axis), after 20 min. D) Mean normal-
ised fluorescence as a function of time for felodipine partitioning
towards a SLB on flat silica, when encapsulated in LVs (blue squares)
and LVs with C8 (red circles). E) Simulation snapshots of felodipine
interacting with lipid membranes, when hosted in LVs without C8 (left
illustration) and LVs with C8 (right illustration). Note, the simulation
included an upper and lower lipid membrane of equal composition
and structure, since the simulation excludes the impact of gravitational
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was also supported by coarse-grained molecular dynamics
simulations which indicated a clear increase in the interaction
with the lipid membrane for LVs with C8 compared to LVs
alone, as shown in the right and left illustration in Figure 2E.
These simulations additionally showed that felodipine parti-
tioned closely to phospholipid molecules within LVs contain-
ing lipid only, with limited drug detachment and partitioning
towards the SLB, while LVs with C8 present promoted
a significant (two-fold) enhancement in the probability of
felodipine detachment from the vesicle into the SLB.
The C8-provoked felodipine partitioning was hypothe-
sized to correlate with enhanced felodipine permeation across
the model lipid membrane. Since it is not possible to observe
permeation across a SLB formed on planar silica, the lipid
bilayer was instead supported on a mesoporous silica
substrate as described above, allowing for time-dependent
drug diffusion across the SLB into the silica pores to be
quantified, using TIRF-confined evanescent wave illumina-
tion restricted to the porous film underneath the SLB. To
correlate permeation with membrane partitioning, the angle
of incidence, q, of the TIRF light source was controlled to
either induce total internal reflection (TIR) at the MSTF-SLB
interface, q1, or using a higher angle of incidence, q2, for TIR
at the silica (cover slip)-MSTF interface (Figure 3A). The
evanescent wave created by light reflecting at the interface
between a material with a higher index of refraction (silica
substrate) and a material with a lower index of refraction
(MSTF) decays exponentially into the material of lower
refractive index.[21] Subsequently, by increasing the angle of
incidence above the critical angle required for TIR at the
silica-MSTF interface, it was possible to limit the depth of
penetration of the evanescent wave to  100–200 nm into the
MSTF pores, as verified by the fluorescence intensity of Rh-
POPC decreasing and the fluorescence intensity of felodipine
increasing as a function of increasing angle of incidence,
measured after 20 min incubation with felodipine in LVs with
C8 (Figure 3 B). Moreover, visual observations of TIRF
micrographs are indicative of LVs and C8 vesicles adsorbed
on the SLB surface at q1 and submicron-sized felodipine
patches observed within the MSTF at q2 (Figure 3C). The
occurrence of submicron (up to micron) sized patches of
felodipine within the MSTF was attributed to the tendency for
the drug to partition in lipid aggregates and the strong
adhesion between lipids and the silica surface within the
porous film. Further, the existence of micron sized disordered
mesoporous phases,[13] which according to observations made
for mesoporous silicon scaffolds[22] may exist as independent
diffusional systems that hamper complete connectivity
throughout the film, could also promote the formation of
small-scale aggregates of water insoluble felodipine and
lipids.
Figure 3. A) Schematic representation of the TIRF experimental set up: a SLB was adsorbed onto a MSTF, whereby the angle of incidence was
adjusted so that total internal reflection occurs at the silica–MSTF interface. This approach allows for identification of felodipine molecules that
are transported across the SLB into the pores of the thin film. B) Fluorescent intensity of the SLB, detected via rhodamine-labelled tracer lipids
(green dots, left axis), and felodipine (red squares, right axis) as a function of angle of incidence. C) TIRF micrographs highlighting the change in
fluorescence intensity and appearance of the SLB and felodipine at angles q1 and q2, as indicated in (B). Scale bars = 20 mm.
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A small increase in fluorescence intensity was observed
when the pure drug was added to buffer alone. In contrast,
felodipine fluorescence intensity within the MSTF pores was
 5-fold greater when administered with LVs, compared to
the pure drug, which is attributed to the solubilizing capacity
of the colloidal phases formed by the phospholipid species
and bile salts (felodipine was added at 80 % its solubility
limit). The ability for C8 to further promote permeation of
felodipine was shown to correlate well with partitioning
studies performed on the planar silica SLB, with a time-
dependent increase in felodipine fluorescence intensity within
the MSTF being observed, leading to a mean normalized
fluorescence intensity of 1048 315 AU after 20 min (Fig-
ure 4C). In particular, analysis of the number and intensity of
submicron felodipine patches within the MSTF after 20 min
demonstrates a  5-fold increase in drug permeation when
administered with LVs and C8, compared to LVs alone
(Figure 4A and B). Changes in normalized fluorescence
intensities due to felodipine permeation across the SLB
displayed kinetics with multiple phases observed upon
addition of LVs including C8 (Figure 4C), where a lag phase
was followed by a rapid and sustained increase in fluorescence
intensity. This contrasts with the changes in normalized
fluorescent intensity when felodipine-encapsulated LVs with
C8 were added to an SLB on planar silica (Figure 2D), where
a rapid increase in fluorescence intensity was observed within
60 s. Thus, the presence of a lag phase for LVs with C8
indicates that C8 must first bind to and insert within the lipid
membrane prior to promoting transport of felodipine across
the lipid membrane, into the pores of the MSTF.
Importantly, the integrity of the SLB was not significantly
disrupted during (or after) exposure to felodipine, when
encapsulated within LVs including C8 (Figure 5). That is,
monitoring of Rh-POPC fluorescence at the MSTF-SLB
interface (q1), concurrently to felodipine permeation,
revealed only a minor time-dependent reduction in fluores-
cence intensity (Figures 5A and C), being attributed to Rh-
POPC molecules within the SLB interchanging with lipids
within LVs. Further, FRAP analysis post-exposure to felodi-
pine demonstrated essentially complete fluorescence recov-
ery within 30 s after photobleaching (Figure 5B), validating
the presence of an intact SLB throughout the drug perme-
ation process. A small increase in diffusion constant was even
observed following felodipine exposure, from 2.8 0.2 mm2 s1
to 3.5 0.7 mm2 s1, which is consistent with previous findings
that demonstrated the ability for saturated fatty acids (e.g.
C8) to facilitate lipid packing and membrane fluidity.[23]
Figure 4. A) TIRF micrographs at various time points highlighting
felodipine permeation across the SLB into the pores of the MSTF,
when solubilized within LVs without a permeation enhancer (top row)
and with C8 (bottom row). Scale bars = 20 mm. B) Fluorescent intensity
distributions for felodipine patches within MSTF when hosted in LVs
(blue bars) and LVs with C8 (red bars). C) Mean normalized fluores-
cence as a function of time for felodipine within MSTF in TRIS buffer
(i.e. pure drug) (green triangles), LVs (blue squares) and LVs with C8
(red circles). Data represents mean  S.D. (n =3).
Figure 5. A) TIRF micrographs highlighting the time-dependent
changes in visual appearance of the rhodamine-labelled SLB when
exposed to felodipine encapsulated within LVs in the presence of C8.
Scale bars = 20 mm. B) TIRF micrographs revealing fluorescence recov-
ery of the rhodamine-labelled SLB after photobleaching. FRAP was
performed on the SLB following exposure to felodipine hosted within
LVs with C8. Thus, the ability for fluorescence recovery within 30 s
after photobleaching indicates the presence of an intact SLB. C) Mean
normalized fluorescence as a function of time for the rhodamine-
labelled SLB during exposure to felodipine hosted within LVs in the
presence of C8. The TIRF angle was set at the MSTF-SLB interface
while monitoring Rh-SLB fluorescence. D) Variations in lipid mem-
brane diffusion constant (green bars, left axis) and relative immobile
fractions (pink checkered bars, right axis) for SLBs pre-exposure to
felodipine hosted within LVs in the presence of C8 (t = 0 min) and
post-exposure (t = 20 min). Data represents mean  S.D. (n= 3).
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In conclusion, TIRF microscopy has for the first time been
used to monitor time-dependent changes in the adsorption
and diffusion of a bioactive drug compound from the bulk
phase, to and through a supported cell-membrane mimic, into
the pores of a mesoporous silica film, thereby directly
assessing in vitro drug permeation across a model lipid
membrane. By harnessing the capabilities of TIRF microsco-
py, it was possible to elucidate the mechanism of action of
a common PE on a model lipid membrane, while discrim-
inating its ability to increase the diffusion and permeation of
a solubilized drug molecule within and across a lipid mem-
brane. Correlations between drug partitioning to a SLB on
a flat surface and permeation across an SLB on a porous
surface revealed that once inserted into the lipid membrane,
felodipine readily diffused across the SLB and into the MSTF.
In comparison with a solid planar support, the MSTF
substrate ensures a more representative quantification of
simulated drug permeation across a biological membrane,
while the distribution within and integrity of the SLB can still
be assessed. While the focus of the current study was to
monitor and validate the C8-induced permeability of a model
drug in simulated oral delivery conditions, the approach has
high potential to be broadly applied for optimizing small-
molecule bioactive permeation across widespread lipid mem-
brane barriers, including cellular membranes and the blood–
brain barrier. Since MSTF may facilitate some degree of
active transport across the SLB,[22] it is critical that permeation
kinetics of the pure drug are investigated as a negative
control, with respect to carrier systems, as this mode of
facilitated transport may be greater for other drug molecules
than that observed for felodipine. It is therefore stipulated
that employing such an approach to estimate drug permeation
will prevent the need for costly and time-exhaustive cellular
assays, while still providing a biologically relevant prediction
for in vivo permeability.
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